AKBM.OL
Aker BioMarine AS [AKBM.OL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
AKBM.OL Stock Summary
Top 10 Correlated Stocks
AKBM.OL
In the News
AKBM.OL Financial details
Company Rating
Neutral
Market Cap
6.01B
Income
-9.1M
Revenue
335.2M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
373
Optionable
No
Shortable
Yes
Earnings
25 Apr 2024
P/E
-25.69
Forward P/E
-
PEG
0.85
P/S
1.17
P/B
1.36
P/C
-
P/FCF
-19.35
Quick Ratio
0.12
Current Ratio
2.9
Debt / Equity
1.07
LT Debt / Equity
0.94
-
-
EPS (TTM)
-0.22
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
6.38%
Revenue Q/Q
-12.37%
EPS Q/Q
-
-
-
-
-
SMA20
6.64%
SMA50
47.82%
SMA100
51.51%
Inst Own
-
Inst Trans
-
ROA
-2%
ROE
-5%
ROC
0.03%
Gross Margin
36%
Oper. Margin
7%
Profit Margin
-6%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
30.35-70.0
52W High
-1.43%
52W Low
+130%
RSI
65.91
Rel Volume
0.91
Avg Volume
42.75K
Volume
38.84K
Perf Week
2.37%
Perf Month
29.21%
Perf Quarter
77.38%
Perf Half Y
76.25%
-
-
-
-
Beta
0.876
-
-
Volatility
1.45%, 3.58%
Prev Close
2.68%
Price
69
Change
5.99%
AKBM.OL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.56 | 3.7 | 2.99 | 3.16 | 0 | |
| Net income per share | -0.34 | -0.07 | -0.09 | 0.11 | 0 | |
| Operating cash flow per share | 0.18 | -0.65 | 0.01 | 0.17 | 0 | |
| Free cash flow per share | -1.66 | -0.96 | -0.92 | -0.35 | 0 | |
| Cash per share | 0.18 | 0.12 | 0.1 | 0.24 | 0 | |
| Book value per share | 2.24 | 4.78 | 4.23 | 4.32 | 0 | |
| Tangible book value per share | -0.52 | 2.47 | 2.27 | 2.46 | 0 | |
| Share holders equity per share | 2.24 | 4.78 | 4.23 | 4.32 | 0 | |
| Interest debt per share | 6.41 | 3.35 | 3.86 | 4.58 | 0 | |
| Market cap | 822.69M | 1.07B | 540.37M | 337.4M | 0 | |
| Enterprise value | 1.23B | 1.3B | 856.06M | 697.6M | 367.6M | |
| P/E ratio | -34.64 | -195.72 | -67.48 | 33.74 | 0 | |
| Price to sales ratio | 3.34 | 3.71 | 2.06 | 1.22 | 0 | |
| POCF ratio | 66.85 | -20.95 | 741.25 | 22.34 | 0 | |
| PFCF ratio | -7.18 | -14.3 | -6.72 | -10.88 | 0 | |
| P/B Ratio | 5.32 | 2.87 | 1.46 | 0.89 | 0 | |
| PTB ratio | 5.32 | 2.87 | 1.46 | 0.89 | 0 | |
| EV to sales | 5 | 4.51 | 3.27 | 2.52 | 1.1 | |
| Enterprise value over EBITDA | 34.87 | 19.53 | 15.04 | 9.23 | 8.03 | |
| EV to operating cash flow | 99.97 | -25.53 | 1.17K | 46.2 | 7.76 | |
| EV to free cash flow | -10.74 | -17.43 | -10.65 | -22.5 | -193.47 | |
| Earnings yield | -0.03 | -0.01 | -0.01 | 0.03 | 0 | |
| Free cash flow yield | -0.14 | -0.07 | -0.15 | -0.09 | 0 | |
| Debt to equity | 2.72 | 0.65 | 0.88 | 1.01 | 1.07 | |
| Debt to assets | 0.61 | 0.35 | 0.43 | 0.46 | 0.48 | |
| Net debt to EBITDA | 11.55 | 3.5 | 5.55 | 4.76 | 8.03 | |
| Current ratio | 1.83 | 3.15 | 3.1 | 2.85 | 2.57 | |
| Interest coverage | -0.07 | 0.99 | 0.43 | 1.09 | 0.16 | |
| Income quality | -0.52 | 9.34 | -0.09 | 1.51 | -5.27 | |
| Dividend Yield | 0 | 0.02 | 0 | 0 | 0 | |
| Payout ratio | 0 | -3.03 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0.08 | 0.06 | 0.07 | 0.05 | 0.06 | |
| Research and developement to revenue | 0.02 | 0.01 | 0.01 | 0.01 | 0 | |
| Intangibles to total assets | 0.27 | 0.26 | 0.23 | 0.2 | 0.19 | |
| Capex to operating cash flow | -10.31 | 0.46 | -111.26 | -3.05 | -1.04 | |
| Capex to revenue | -0.52 | -0.08 | -0.31 | -0.17 | -0.15 | |
| Capex to depreciation | -3.44 | -0.49 | -1.59 | -0.93 | -0.98 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 4.16 | 2.74 | 2.95 | 3.33 | 0 | |
| ROIC | 0 | -0.23 | 0.01 | 0.02 | 0 | |
| Return on tangible assets | -0.05 | -0.01 | -0.01 | 0.02 | -0.01 | |
| Graham Net | -6.92 | -2.39 | -3.53 | -3.78 | 0 | |
| Working capital | 83.01M | 152.18M | 162.22M | 194M | 177.3M | |
| Tangible asset value | -35.75M | 192.62M | 198.84M | 216M | 211.1M | |
| Net current asset value | -355.08M | -104.14M | -147.57M | -145M | -170.4M | |
| Invested capital | 2.72 | 0.65 | 0.88 | 1.01 | 1.07 | |
| Average receivables | 0 | 49.74M | 49.74M | 0 | 0 | |
| Average payables | 17.4M | 21.8M | 22.75M | 32.12M | 34.55M | |
| Average inventory | 69.21M | 104.64M | 126.39M | 160.46M | 183.2M | |
| Days sales outstanding | 0 | 125.81 | 0 | 0 | 0 | |
| Days payables outstanding | 56.46 | 41.3 | 52.96 | 87.65 | 49.4 | |
| Days of inventory on hand | 229.14 | 233.58 | 289.95 | 410.63 | 301.49 | |
| Receivables turnover | 0 | 2.9 | 0 | 0 | 0 | |
| Payables turnover | 6.46 | 8.84 | 6.89 | 4.16 | 7.39 | |
| Inventory turnover | 1.59 | 1.56 | 1.26 | 0.89 | 1.21 | |
| ROE | -0.15 | -0.01 | -0.02 | 0.03 | -0.02 | |
| Capex per share | -1.84 | -0.3 | -0.93 | -0.53 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.9 | 0.79 | 1.11 | 0.86 | 0 | |
| Net income per share | 0 | -0.2 | -0.03 | 0.01 | 0 | |
| Operating cash flow per share | 0.28 | -0.06 | -0.19 | 0.18 | 0 | |
| Free cash flow per share | 0.06 | -0.16 | -0.27 | 0.09 | 0 | |
| Cash per share | 0.24 | 0.34 | 0.1 | 0.11 | 0 | |
| Book value per share | 4.32 | 4.07 | 4.4 | 3.25 | 0 | |
| Tangible book value per share | 2.46 | 2.24 | 2.42 | 1.8 | 0 | |
| Share holders equity per share | 4.32 | 4.07 | 4.4 | 3.25 | 0 | |
| Interest debt per share | 4.52 | 4.68 | 5.29 | 3.7 | 0 | |
| Market cap | 337.43M | 327.55M | 252.25M | 396.11M | 0 | |
| Enterprise value | 697.63M | 700.25M | 650.75M | 784.01M | 367.6M | |
| P/E ratio | 843.57 | -4.65 | -25.23 | 90.03 | 0 | |
| Price to sales ratio | 4.27 | 4.74 | 2.85 | 4.19 | 0 | |
| POCF ratio | 13.66 | -60.66 | -17.04 | 19.51 | 0 | |
| PFCF ratio | 68.86 | -23.74 | -11.73 | 38.09 | 0 | |
| P/B Ratio | 0.89 | 0.92 | 0.72 | 1.11 | 0 | |
| PTB ratio | 0.89 | 0.92 | 0.72 | 1.11 | 0 | |
| EV to sales | 8.83 | 10.13 | 7.34 | 8.29 | 4.43 | |
| Enterprise value over EBITDA | 24.65 | 269.33 | 34.61 | 32.26 | 102.11 | |
| EV to operating cash flow | 28.24 | -129.68 | -43.97 | 38.62 | 7.77 | |
| EV to free cash flow | 142.37 | -50.74 | -30.27 | 75.39 | 16.05 | |
| Earnings yield | 0 | -0.05 | -0.01 | 0 | 0 | |
| Free cash flow yield | 0.01 | -0.04 | -0.09 | 0.03 | 0 | |
| Debt to equity | 1.01 | 1.13 | 1.17 | 1.14 | 1.07 | |
| Debt to assets | 0.46 | 0.49 | 0.5 | 0.5 | 0.48 | |
| Net debt to EBITDA | 12.73 | 143.35 | 21.2 | 15.96 | 102.11 | |
| Current ratio | 2.85 | 2.62 | 3.34 | 2.9 | 2.57 | |
| Interest coverage | 1.09 | -1.24 | 0.61 | 0 | 0 | |
| Income quality | 123.5 | 0.31 | 6.17 | 18.45 | 4.78 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | -0.63 | 0.37 | 0.21 | 0.2 | -0.51 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.2 | 0.2 | 0.19 | 0.19 | 0.19 | |
| Capex to operating cash flow | -0.8 | 1.56 | 0.45 | -0.49 | -0.52 | |
| Capex to revenue | -0.25 | -0.12 | -0.08 | -0.1 | -0.29 | |
| Capex to depreciation | -1.64 | -0.7 | -0.53 | -0.72 | -2.16 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.33 | 4.29 | 1.76 | 0.85 | 0 | |
| ROIC | 0 | -0.01 | 0 | 0.01 | 0 | |
| Return on tangible assets | 0 | -0.03 | 0 | 0 | 0.01 | |
| Graham Net | -3.78 | -3.87 | -4.56 | -3.22 | 0 | |
| Working capital | 194M | 182.6M | 209.8M | 196.8M | 177.3M | |
| Tangible asset value | 216M | 196.6M | 193.2M | 198.5M | 211.1M | |
| Net current asset value | -145M | -165.3M | -168M | -157.8M | -170.4M | |
| Invested capital | 1.01 | 1.13 | 1.17 | 1.14 | 1.07 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 37.95M | 44.85M | 48.65M | 45.3M | 37.05M | |
| Average inventory | 181.6M | 183.6M | 186.35M | 185.7M | 183.45M | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 74.36 | 94.67 | 71.45 | 66.67 | 48.29 | |
| Days of inventory on hand | 348.37 | 344.5 | 288.55 | 277.58 | 294.71 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.21 | 0.95 | 1.26 | 1.35 | 1.86 | |
| Inventory turnover | 0.26 | 0.26 | 0.31 | 0.32 | 0.31 | |
| ROE | 0 | -0.05 | -0.01 | 0 | 0.03 | |
| Capex per share | -0.23 | -0.1 | -0.08 | -0.09 | 0 |
AKBM.OL Frequently Asked Questions
What is Aker BioMarine AS stock symbol ?
Aker BioMarine AS is a NO stock and trading under the symbol AKBM.OL
What is Aker BioMarine AS stock quote today ?
Aker BioMarine AS stock price is $69 today.
Is Aker BioMarine AS stock public?
Yes, Aker BioMarine AS is a publicly traded company.
Company Profile
- Volume Average 42.75K
- Market Capitalization 6.01B
- Employee 373
- CEO Mr. Matts Johansen
- Headquarters Lysaker,NO
- IPO Date 2020-07-06
-
Website
https://www.akerbiomarine.com 
Aker BioMarine AS develops, produces, and sells krill-derived ingredients for nutraceutical, dietary supplement, and animal feed applications in Norway, the Americas, the Asia Pacific, Europe, the Middle East, and Africa. It operates through two segments, Ingredients and Brands. It provides Superba, a krill-based ingredients for nutraceutical, including phospholipid complex of choline, omega-3s, and antioxidant astaxanthin; QRILL Aqua, a krill-based ingredients for aquaculture; and QRILL Pet, a krill-based ingredients animal feed application. The company also offers LYSOVETA, a delivery platform based on LPC-bound EPA and DHA from krill; and INVI, a hydrolyzed protein isolate for food and beverage applications. In addition, it distributes human health and nutrition products, and natural supplements, as well as provides AION, a circular solution provider that recycles waste and re-use materials. The company was founded in 2006 and is headquartered in Lysaker, Norway. Aker BioMarine ASA is a subsidiary of Aker ASA.
